Clinical trial
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
NCT00157950 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00157950 |
|---|---|
| Title | Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) |
| Official title | An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections |
| Intervention type | Biological |
| Interventions | Gardasil™, Placebo |
| Enrollment | 176 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 4, 2016 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: